by David Wagner | Mar 7, 2025 | Equity Case Studies, Equity Research
Before we highlight one of the Aptus Compounder’s holdings (15-stock, high-conviction strategy – shoot me an email if you have any questions on this unpackaged SMA strategy), let’s touch base on two things today: Given the recent volatility, if you have...
by Aptus PM Team | Jul 23, 2024 | Equity Research, Market Updates
U.S. large caps, as measured by the S&P 500, continued their dominance in the first half of 2024, led by the largest mega-cap stocks, coined The Magnificent Seven (“Mag 7”). This year’s first half ranks as the 12th-best start for the S&P 500 since 1950 – the...
by Aptus PM Team | Apr 10, 2024 | Equity Research
It causes Aptus much chagrin that the widespread notoriety for bourbon only started in the early 1980s, almost two hundred years after Kentucky started distilling an unlikely combination of corn and limestone water. Nobody knows, definitively, the origin of bourbon,...
by David Wagner | Mar 8, 2024 | Equity Research
Topics for this Musing: Quick Market Commentary Stock of the Quarter Before I start, please remember that we do great individual stock work for concentrated positions of clients. I have opinions and convictions that I’m more than willing to spew. We were very...
by David Wagner | Dec 5, 2023 | Equity Case Studies, Equity Research
In today’s report, we’ll be covering Chemed Corporation (“CHE”) – in our opinion, one of the last, great remaining publicly traded conglomerate companies. Conglomerates were in vogue for the majority of the 20th century. They came about because most of the mergers in...
by David Wagner | Jul 25, 2023 | Equity Case Studies, Equity Research
On recent travels, I’ve been doing some thinking on the overall valuation of the domestic market – alongside reading a few differentiated thoughts on the matter. I don’t want to go as far as saying that investors need to be discounting a revolutionary change in the...
